|
Synonyms: BIIB-033 | BIIB033
Compound class:
Antibody
Comment: Opicinumab is a monoclonal antibody which acts as a functional antagonist of the neural protein, LINGO1 [2-3]. Opicinumab was investigated for its clinical utility in diseases with underlying immune-driven demyelination.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A BLAST search of patented peptide sequences reveals a 100% match between the variable heavy chain region of opicinumab and SEQ ID NO: 5 from patent US8058406 B2, and another identical match between the variable light chain of the antibody and the patent's SEQ ID NO: 13 [2]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Opicinumab reached Phase 2 clinical trial as a potential therapy for multiple sclerosis (MS) and for acute demyelinating optic neuritis [6]. Phase 1 results were reported in [7], which indicated good satety, tolerability and pharmacokinetic profiles in healthy subjects and MS patients. In 2020 Biogen terminated this clinical programme in response to results from their phase 2 AFFINITY study in MS which did not meet its primary or secondary endpoints. |
| Mechanism Of Action and Pharmacodynamic Effects |
| The mechanism of LINGO1 blockade as a CNS repair therapeutic is reveiewd in [4] and [5]. Anti-LINGO1 antibody treatment promotes oligodendrocyte survival, differentiation and myelination in vitro and in vivo [2] in disease models. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02833142 | Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes | Phase 1 Interventional | Biogen | 7 | |
| NCT03222973 | Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | Phase 2 Interventional | Biogen | Known as the AFFINITY study: failed to meet primary and secondary endpoints, leading to termination of Biogen's opicinumab programme in October 2020. | |
| NCT01721161 | BIIB033 In Acute Optic Neuritis (AON) | Phase 2 Interventional | Biogen | The RENEW study: no significant difference in the remyelination was detected between the opicinumab and placebo groups following 24 weeks in the trial. The treatment group received 6 doses (100 mg/kg i.v.) over the 24 week treatment period. | 1 |
